Why Peer Review Matters More Than Most Patients Ever Realize

Author: Dr. Sam Ward, MD, FEBU, FECSM, FGPS Published: September 2026 Last medically reviewed: September 2026

Joining the Reviewer Board of EMJ Urology

Every guideline a doctor follows, every drug approved for use, and every “new” treatment that makes its way into a clinic has gone through a process that almost no patient ever sees: peer review. It takes place before a study is published—often years before a treatment reaches a doctor’s office—and it is rarely discussed outside of academic circles.

I was recently invited to join the Reviewer Board of EMJ Urology, the peer-reviewed journal published by the European Medical Journal group. This is a good opportunity to explain what that role actually entails, and why peer review deserves more attention than it usually gets, especially in a field like urology and andrology, where new devices, new energy-based therapies, and new “regenerative” treatments are emerging at a steady pace.

What Peer Review Actually Is

When researchers submit a study to a medical journal, it does not go directly to print. Before publication, the manuscript is sent to independent specialists in the same field—reviewers who were not involved in the research—who read it carefully and evaluate it on several fronts:

• Is the methodology sound? Was the study designed in a way that can actually answer the question it poses?
• Do the results support the conclusions? A common pitfall is a paper that exaggerates what its own data shows.
• Is the statistical analysis appropriate for the sample size and study design?
• Are the risks, limitations, and conflicts of interest clearly disclosed?
• Does the work add something meaningful to what is already known, or does it duplicate existing evidence without acknowledging it?

Reviewers send their evaluations back to the journal’s editors, who decide whether to accept, reject, or return the paper to the authors for revision. Often, a manuscript goes through several rounds of this process before it is deemed ready for publication. None of this is paid work. It is done by clinicians and researchers, in addition to their own clinical and academic responsibilities, because the integrity of the published literature depends on it.

Why this matters more in a rapidly evolving field

Urology and andrology occupy an interesting intersection. On the one hand, they are rooted in long-established surgical and medical practice. On the other, they are fields where new technology is constantly emerging: shockwave devices, platelet-rich plasma protocols, traction therapies, robotic techniques, and digital health tools. Each of these typically begins with a small pilot study, promising results, and a wave of enthusiasm—sometimes from clinicians, often from industry.

The gap between “a pilot study showed promising results” and “this is a proven, guideline-supported treatment” is precisely where peer review comes into play. A well-designed randomized controlled trial with a plausible mechanism of action and consistent replication is quite different from a small, uncontrolled case series accompanied by a strong marketing narrative. Peer review is one of the main mechanisms that ensures this distinction remains clear in the published literature—before it is incorporated into clinical guidelines and before it reaches patients.

This is also why, when I discuss emerging treatments with patients, I try to be clear about where a treatment falls on that spectrum: established and supported by clinical guidelines, moderately supported by evidence, or still emerging and investigational. That distinction exists because of the work done—largely behind the scenes—by reviewers.

What the role entails

As a member of the EMJ Urology Reviewer Board, I will be reviewing submitted manuscripts in my areas of clinical expertise—male sexual health, erectile dysfunction, Peyronie’s disease, penile prosthetic surgery, and reconstructive andrology—to assess whether the scientific evidence holds up before it is published. This complements the peer-review work I already do as part of my role with the European Society for Sexual Medicine (ESSM), and it reflects the same underlying principle: evidence should be rigorously tested before it changes how patients are treated.

The Bigger Picture

Patients rarely see any of this. They see a headline, a device advertised online, or a treatment recommended by a friend. What they don’t see is the level of scrutiny—or the lack thereof—that distinguishes a therapy backed by genuine evidence from one that simply has good marketing. Part of the reason I’m involved in peer review, guideline development, and scientific publishing is that this scrutiny is what ultimately protects patients from treatments that promise more than the evidence supports.

It is slow, unglamorous work. It is also one of the more meaningful ways a clinician can contribute to a field beyond their own consulting room.

This article provides general professional information and does not constitute personalized medical advice. For questions about a specific treatment or condition, please consult your doctor.